Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRI NASDAQ:HCM NASDAQ:SLN NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRIGRI Bio$1.62-6.9%$2.05$1.59▼$80.36$3.08M-1.21105,371 shs54,678 shsHCMHUTCHMED$11.14+0.6%$11.40$9.77▼$19.50$1.93B0.2447,306 shs38,353 shsSLNSilence Therapeutics$9.29+2.2%$7.63$4.19▼$11.06$429.36M1.38600,565 shs233,638 shsSLSSELLAS Life Sciences Group$12.62-1.1%$9.14$1.39▼$15.88$2.51B2.4210.83 million shs5.15 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRIGRI Bio-6.90%-10.50%-28.00%-33.61%-96.51%HCMHUTCHMED+0.63%-4.38%+1.64%-26.76%-30.55%SLNSilence Therapeutics+2.20%-12.19%+38.86%+51.80%+44.25%SLSSELLAS Life Sciences Group-1.10%-9.47%+61.17%+159.67%+585.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRIGRI Bio$1.62-6.9%$2.05$1.59▼$80.36$3.08M-1.21105,371 shs54,678 shsHCMHUTCHMED$11.14+0.6%$11.40$9.77▼$19.50$1.93B0.2447,306 shs38,353 shsSLNSilence Therapeutics$9.29+2.2%$7.63$4.19▼$11.06$429.36M1.38600,565 shs233,638 shsSLSSELLAS Life Sciences Group$12.62-1.1%$9.14$1.39▼$15.88$2.51B2.4210.83 million shs5.15 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRIGRI Bio-6.90%-10.50%-28.00%-33.61%-96.51%HCMHUTCHMED+0.63%-4.38%+1.64%-26.76%-30.55%SLNSilence Therapeutics+2.20%-12.19%+38.86%+51.80%+44.25%SLSSELLAS Life Sciences Group-1.10%-9.47%+61.17%+159.67%+585.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRIGRI Bio 2.00Hold$32.001,875.31% UpsideHCMHUTCHMED 2.20Hold$15.3037.34% UpsideSLNSilence Therapeutics 2.83Moderate Buy$55.00492.03% UpsideSLSSELLAS Life Sciences Group 2.33Hold$10.00-20.76% DownsideCurrent Analyst Ratings BreakdownLatest SLN, HCM, GRI, and SLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2026HCMHUTCHMED Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $17.007/6/2026SLSSELLAS Life Sciences Group Alliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/29/2026HCMHUTCHMED Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)6/24/2026SLNSilence Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight6/17/2026SLNSilence Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.006/1/2026GRIGRI Bio Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $32.005/28/2026HCMHUTCHMED Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.605/1/2026HCMHUTCHMED Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/21/2026GRIGRI Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SLNSilence Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SLSSELLAS Life Sciences Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRIGRI BioN/AN/AN/AN/A$4.16 per shareN/AHCMHUTCHMED$548.51M3.54$2.71 per share4.11$7.17 per share1.55SLNSilence Therapeutics$560K783.68N/AN/A$1.32 per share7.04SLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRIGRI Bio-$11.96M-$74.16N/AN/AN/AN/A-199.52%-143.23%8/13/2026 (Estimated)HCMHUTCHMED$456.91MN/AN/A39.79N/AN/AN/AN/A7/30/2026 (Estimated)SLNSilence Therapeutics-$88.61M-$1.59N/AN/AN/A-8,943.86%-105.34%-52.79%8/6/2026 (Estimated)SLSSELLAS Life Sciences Group-$26.86M-$0.23N/AN/AN/AN/A-47.12%-42.63%8/11/2026 (Estimated)Latest SLN, HCM, GRI, and SLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026N/ASLSSELLAS Life Sciences Group-$0.0450N/AN/AN/AN/AN/A8/6/2026Q2 2026SLNSilence Therapeutics-$0.1387N/AN/AN/A$1.17 millionN/A7/30/2026H1 2026HCMHUTCHMED$0.15N/AN/AN/A$306.40 millionN/A5/13/2026Q1 2026GRIGRI Bio-$1.6050-$1.61-$0.0050-$1.61N/AN/A5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/A5/8/2026Q1 2026SLNSilence Therapeutics-$0.1850-$0.32-$0.1350-$0.33$1.26 million$0.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGRIGRI BioN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRIGRI BioN/A14.2014.21HCMHUTCHMED0.054.964.83SLNSilence TherapeuticsN/A9.839.83SLSSELLAS Life Sciences GroupN/A17.2217.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRIGRI Bio33.95%HCMHUTCHMED8.82%SLNSilence Therapeutics98.73%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipGRIGRI Bio8.73%HCMHUTCHMED3.60%SLNSilence Therapeutics3.00%SLSSELLAS Life Sciences Group1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRIGRI Bio11.77 million1.62 millionNot OptionableHCMHUTCHMED1,796174.47 million168.19 millionNot OptionableSLNSilence Therapeutics10047.24 million45.82 millionNot OptionableSLSSELLAS Life Sciences Group10196.63 million194.08 millionNot OptionableSLN, HCM, GRI, and SLS HeadlinesRecent News About These CompaniesInvestors Purchase High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)July 13 at 1:39 PM | marketbeat.comSellas Life Sciences: REGAL Trial's Delayed Events Signal Selection BiasJuly 9, 2026 | seekingalpha.comHere’s Why SELLAS (SLS) is Among the 10 Best Performing American Stocks in June 2026July 9, 2026 | finance.yahoo.comSLS stock in the spotlight as CEO pushes back on Regal trial criticism – 'Let's separate the noise from the data'July 8, 2026 | msn.comMost and least shorted mid- to mega-cap healthcare stocks at the end of JuneJuly 1, 2026 | seekingalpha.comSELLAS Life Sciences Group (SLS) Stock Looks Above Fair Value Before Key Trial DataJuly 1, 2026 | finance.yahoo.comDoes SELLAS (SLS) Executive Severance Reset Hint at M&A Readiness or Standalone Ambition?June 30, 2026 | uk.finance.yahoo.comWhy Sellas Remains A Strong Sell After Doubling In PriceJune 30, 2026 | seekingalpha.comSELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?June 30, 2026 | benzinga.comSellas Life (SLS) Climbs to Record High on Acquisition BuzzJune 30, 2026 | finance.yahoo.comSellas Life Sciences shares break out to new 52-week high: What's driving the momentum?June 29, 2026 | msn.comIs SELLAS Life Sciences Group, Inc. (SLS) A Good Stock To Buy Now?June 29, 2026 | insidermonkey.comWhy did SLS, MRNA, ABCL stocks surge to 52-week highs last week?June 28, 2026 | msn.comSellas Life Sciences: The AML Platform Is More Interesting Than The Binary EventJune 27, 2026 | seekingalpha.comSELLAS Life Sciences jumps as traders focus on imminent REGAL trial catalyst and stronger cash positionJune 26, 2026 | quiverquant.comQSELLAS stock hits new highs: What's happening today?June 26, 2026 | msn.comWhat's driving SLS stock higher today and what comes next?June 26, 2026 | invezz.comISLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout ChatterJune 26, 2026 | finance.yahoo.comSellas (SLS) Extends Rally, New Filing Hints at Company TakeoverJune 26, 2026 | insidermonkey.comSLS stock up 13% as executive severance updates reignite buyout speculationJune 25, 2026 | msn.comSLS stock slips overnight: Shareholders approve 20M new shares, CEO awarded 1M RSUsJune 22, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesShorting the Grid: Bloom Energy’s $25B AI Power PlayBy Jeffrey Neal Johnson | July 2, 2026Chevron’s Microsoft Deal Turns Natural Gas Into an AI TradeBy Jeffrey Neal Johnson | June 24, 2026Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and GrainsBy Bridget Bennett | July 6, 2026GE Vernova’s Power Surge Turns the Grid Into an AI TradeBy Ryan Hasson | July 7, 2026Top 135 Best Locally Owned BBQ Supply Stores in the U.S., According to Survey [2026]By MarketBeat Staff | July 7, 2026SLN, HCM, GRI, and SLS Company DescriptionsGRI Bio NASDAQ:GRI$1.62 -0.12 (-6.90%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$1.62 0.00 (-0.06%) As of 07/13/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.HUTCHMED NASDAQ:HCM$11.14 +0.07 (+0.63%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$11.14 -0.01 (-0.04%) As of 07/13/2026 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Silence Therapeutics NASDAQ:SLN$9.29 +0.20 (+2.20%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$9.27 -0.02 (-0.26%) As of 07/13/2026 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.SELLAS Life Sciences Group NASDAQ:SLS$12.62 -0.14 (-1.10%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$12.52 -0.09 (-0.75%) As of 07/13/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Analysts See Major Upside for These 5 Stocks One Short- and One Long-Term ETF for Quantum Computing Bulls Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
